Are you looking for ways to choose strong stocks that can outperform the market for your investment portfolio? The Zacks Style Scores can help you with that.
Investors looking at Medical - Biomedical and Genetics stocks may have come across BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). The question is, which of these two stocks provides better value for investors at this moment?
BioMarin (BMRN) has strong growth characteristics that may enable it to significantly exceed market performance.
BioMarin Pharmaceutical (BMRN 4.75%) saw a lot of activity in its stock on Thursday after it announced its latest quarterly results. Excited investors pushed the company's shares up by almost 5%, which was a big difference compared to the 0.4% drop in the S&P 500 index that day.
BMRN has announced fourth-quarter results that exceeded expectations, thanks to strong demand for Voxzogo. The company maintains its forecast of reaching $4 billion in total sales by 2027.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will hold its Q4 2024 Earnings Conference Call on February 19, 2025, at 4:30 PM ET. The call will feature key company participants, including Traci McCarty, Alexander Hardy, and Brian Mueller, among others. Attendees from various financial institutions will also join the call, and the operator has muted all lines to minimize background noise.
The financial results for BioMarin (BMRN) from the quarter ending in December 2024 provide insight into the company's performance. It may be helpful to compare some important metrics with Wall Street predictions and figures from the same period last year.
BioMarin Pharmaceutical (BMRN) reported quarterly earnings of $0.92 per share, which is higher than the Zacks Consensus Estimate of $0.73 per share. This is an increase compared to earnings of $0.49 per share from the same period last year.
In 2024, effective execution and operational changes led to record results, setting the stage for strong revenue and profit growth in 2025. The total revenue for the fourth quarter of 2024 reached $747 million, which is a 16% increase compared to the previous year, and an 18% increase for the entire year, totaling $2.85 billion. A conference call and webcast will take place today at 4:30 p.m. ET from San Rafael, California.
When BMRN shares its earnings for the fourth quarter, investors are expected to pay close attention to how well its dwarfism medication, Voxzogo, is selling.